middle.news
Neuren Nets $50M from Rare Disease Voucher Sale Boosting Neurological Pipeline
12:03pm on Friday 7th of February, 2025 AEDT
•
Pharmaceuticals
Read Story
Neuren Nets $50M from Rare Disease Voucher Sale Boosting Neurological Pipeline
12:03pm on Friday 7th of February, 2025 AEDT
Key Points
Neuren receives one-third share of US$150 million Priority Review Voucher sale
Voucher granted by FDA after approval of DAYBUE™ for Rett syndrome
Proceeds provide substantial capital boost for Neuren’s drug development
Neuren’s NNZ-2591 advancing with positive Phase 2 clinical trial results
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE